

Details of Q4 FY23 Quarterly Report, Appendix 4C & Webinar

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) will release its Q4 FY23 Quarterly Activities Report & Appendix 4C on Thursday, 27 July 2023.

The Company will host an investor webinar with CEO Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro at 10:30am AEST on Thursday, 27 July 2023.

Presenting: CEO, Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro

Time: 10:30am AEST on Thursday, 27 July 2023

To register for the session and for more information on the conference click on the below link:

[Microba Q4 FY23 Investor Webinar Registration](#)

Investors can submit questions prior to the webinar to simon@nwrcommunications.com.au or do so via the Q&A functions on Zoom during the webinar.

This announcement has been authorised for release by the Chairman and CEO.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

E: simon@nwrcommunications.com.au

T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.

Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.